Exhibits acetylcholine binding activity and acetylcholine-gated cation-selective channel activity. Predicted to contribute to acetylcholine receptor activity. Involved in cholinergic synaptic transmission and regulation of acetylcholine-gated cation channel activity. Localizes to several cellular components, including cholinergic synapse; integral component of plasma membrane; and neuronal cell body. Biomarker of congestive heart failure. Human ortholog(s) of this gene implicated in autosomal dominant nocturnal frontal lobe epilepsy 1 and nicotine dependence. Orthologous to human CHRNA4 (cholinergic receptor nicotinic alpha 4 subunit); PARTICIPATES IN acetylcholine signaling pathway via nicotinic acetylcholine receptor; alfentanil pharmacodynamics pathway; bupivacaine pharmacodynamics pathway; INTERACTS WITH (S)-anabasine; (S)-nicotine; 17alpha-ethynylestradiol.
[Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein] more ...
1-5-azido-6-chloropyridin-3-ylmethyl-2-nitroiminoimidazolidine inhibits the reaction [Nicotine analog binds to [CHRNA4 protein co-treated with CHRNB2 protein]] more ...
[N-2-cyclohexyloxy-4-nitrophenylmethanesulfonamide co-treated with Nicotine] inhibits the reaction [N-2-cyclohexyloxy-4-nitrophenylmethanesulfonamide results in increased expression of CHRNA4 protein] more ...
tetrabromobisphenol A inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]], tetrabromobisphenol A inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein co-treated with CHRNB2 protein]]
N-Methyl-3, 4-methylenedioxyamphetamine inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein co-treated with CHRNB2 protein]]
[CHRNA4 protein co-treated with CHRNB2 protein mutant form] inhibits the reaction [Calcium results in increased susceptibility to Acetylcholine] more ...
Alcuronium inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]], Alcuronium results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]
[ponceau 4R co-treated with Allura Red AC Dye co-treated with 6-hydroxy-5-p- sulfophenylazo-2-naphthalenesulfonic acid disodium salt co-treated with Tartrazine co-treated with Amaranth Dye co-treated with brilliant blue co-treated with Indigo Carmine] results in decreased expression of CHRNA4 protein
Atropine promotes the reaction [Mecamylamine inhibits the reaction [Paraoxon results in decreased expression of CHRNA4 mRNA]], Atropine promotes the reaction [Mecamylamine inhibits the reaction [Paraoxon results in decreased expression of CHRNA4 protein]]
[CHRNA4 protein co-treated with CHRNB2 protein] affects the reaction [Barium results in increased susceptibility to Acetylcholine], [CHRNA4 protein mutant form co-treated with CHRNB2 protein] inhibits the reaction [Barium results in increased susceptibility to Acetylcholine]
[ponceau 4R co-treated with Allura Red AC Dye co-treated with 6-hydroxy-5-p- sulfophenylazo-2-naphthalenesulfonic acid disodium salt co-treated with Tartrazine co-treated with Amaranth Dye co-treated with brilliant blue co-treated with Indigo Carmine] results in decreased expression of CHRNA4 protein
[CHRNA4 protein co-treated with CHRNB2 protein mutant form] inhibits the reaction [Calcium results in increased susceptibility to Acetylcholine] more ...
[CHRNA4 protein co-treated with CHRNB2 protein mutant form] inhibits the reaction [Calcium results in increased susceptibility to Acetylcholine] more ...
Carbaryl results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein], Carbaryl results in decreased activity of [CHRNA4 protein binds to CHRNB4 protein]
Choline affects the activity of [CHRNA4 protein binds to CHRNB2 protein], Choline inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]
Dihydro-beta-Erythroidine binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein], Dihydro-beta-Erythroidine inhibits the reaction [3-2-pyrrolidinylmethoxypyridine analog results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]
Carbachol inhibits the reaction [Dihydro-beta-Erythroidine binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] more ...
[Dihydro-beta-Erythroidine binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] which results in decreased susceptibility to Nicotine more ...
EPTC results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein], EPTC results in decreased activity of [CHRNA4 protein binds to CHRNB4 protein]
fenoxycarb results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein], fenoxycarb results in decreased activity of [CHRNA4 protein binds to CHRNB4 protein]
Hexamethonium inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]], Hexamethonium results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]
imidacloprid analog inhibits the reaction [Nicotine analog binds to [CHRNA4 protein co-treated with CHRNB2 protein]], imidacloprid binds to [CHRNA4 protein co-treated with CHRNB2 protein]
[ponceau 4R co-treated with Allura Red AC Dye co-treated with 6-hydroxy-5-p- sulfophenylazo-2-naphthalenesulfonic acid disodium salt co-treated with Tartrazine co-treated with Amaranth Dye co-treated with brilliant blue co-treated with Indigo Carmine] results in decreased expression of CHRNA4 protein
[Mercuric Chloride co-treated with Acetylcholine] affects the activity of [CHRNA4 protein binds to CHRNB2 protein], [Mercuric Chloride co-treated with Acetylcholine] affects the activity of [CHRNA4 protein binds to CHRNB4 protein]
1-5-azido-6-chloropyridin-3-ylmethyl-2-nitroiminoimidazolidine inhibits the reaction [Nicotine analog binds to [CHRNA4 protein co-treated with CHRNB2 protein]] more ...
[N-2-cyclohexyloxy-4-nitrophenylmethanesulfonamide co-treated with Nicotine] inhibits the reaction [N-2-cyclohexyloxy-4-nitrophenylmethanesulfonamide results in increased expression of CHRNA4 protein] more ...
[N-2-cyclohexyloxy-4-nitrophenylmethanesulfonamide co-treated with Nicotine] inhibits the reaction [N-2-cyclohexyloxy-4-nitrophenylmethanesulfonamide results in increased expression of CHRNA4 protein]
[ponceau 4R co-treated with Allura Red AC Dye co-treated with 6-hydroxy-5-p- sulfophenylazo-2-naphthalenesulfonic acid disodium salt co-treated with Tartrazine co-treated with Amaranth Dye co-treated with brilliant blue co-treated with Indigo Carmine] results in decreased expression of CHRNA4 protein
[ponceau 4R co-treated with Allura Red AC Dye co-treated with 6-hydroxy-5-p- sulfophenylazo-2-naphthalenesulfonic acid disodium salt co-treated with Tartrazine co-treated with Amaranth Dye co-treated with brilliant blue co-treated with Indigo Carmine] results in decreased expression of CHRNA4 protein
Atropine promotes the reaction [Mecamylamine inhibits the reaction [Paraoxon results in decreased expression of CHRNA4 mRNA]], Atropine promotes the reaction [Mecamylamine inhibits the reaction [Paraoxon results in decreased expression of CHRNA4 protein]]
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin